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Adenoviruses  have  been  shown  to be both  immunogenic  and  efﬁcient  at presenting  HIV proteins  but
recent  trials have  suggested  that  they  may  play  a role  in increasing  the  risk  of  HIV  acquisition.  This
risk  may  be  associated  with  the  presence  of pre-existing  immunity  to  the  viral  vectors.  Chimpanzee
adenoviruses  (chAd)  have  low  seroprevalence  in  human  populations  and  so  reduce  this  risk.  ChAd3  and
chAd63  were  used  to  deliver  an  HIV gag,  pol  and  nef  transgene.  ELISpot  analysis  of  T  cell  responses  in
mice  showed  that  both  chAd  vectors  were  able  to  induce  an  immune  response  to  Gag and  Pol  peptidesIV
accine
denovirus
ouse
ectors
mmunogenicity
but  that  only  the  chAd3  vector  induced  responses  to Nef peptides.  Although  the  route  of  injection  did
not  inﬂuence  the magnitude  of  immune  responses  to either  chAd  vector,  the  dose  of vector  did.  Taken
together  these  results  demonstrate  that  chimpanzee  adenoviruses  are  suitable  vector  candidates  for  the
delivery  of HIV proteins  and  could  be  used  for an  HIV  vaccine  and  furthermore  the chAd3  vector  produces
a  broader  response  to the  HIV transgene.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
The search for an effective, prophylactic HIV vaccine has been
omplicated by evidence that pre-existing immunity to some of the
ost commonly used human recombinant adenovirus (rAd)-based
iral vectors have suppressed the effectiveness of vaccination and
lso may  have enhanced the risk of HIV infection in some clinical
rial populations [1–3]. The ﬁnding that the adenovirus subtype 5
sed in the Merck STEP trial was associated with a higher incidence
f HIV infection in uncircumcised males, who were seropositive for
d5 has been linked by some investigators to the recruitment of
ctivated CD4 T cells to the site of infection.
Many other viral and non-viral vectors have been tried and
ested but have failed to provoke an efﬁcient immune response
reviewed in [4]). Alternative human rAd HIV vaccines, based
n strains less prevalent in humans have been shown to be
mmunogenic (reviewed in [5]). In addition, reports looking at ade-
oviruses from non-human species have shown that chimpanzee
∗ Corresponding author. Tel.: +44 1784 443545.
E-mail address: G.Dickson@rhul.ac.uk (G. Dickson).
1 Contributed equally to the work.
ttp://dx.doi.org/10.1016/j.vaccine.2015.10.111
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uadenoviruses (chAds) may  offer promise as potential HIV vaccines
being immunogenic in mice and non-human primates [6–8].
ChAd type 3 (chAd3) and chAd type 63 (chAd63) have low
seroprevalence within the populations from Africa, the Americas
and India and when encoding HIV or SIV gag as a transgene were
as effective as Ad5 at eliciting a T cell responses and compared
favourably to alternative human rAds [9]. In addition, chAd3 encod-
ing Gag/Pol from SIV strain mac239 induced comparable CD8 T cell
immunity to rAd5 in mice and a chAd63 vectored vaccine with
an antigen based on conserved HIV-1 subprotein regions has been
tested and shown to be safe and immunogenic in humans [10,11].
ChAd3 and 63 vectors have also been tested, with promising results,
as vaccines for Hepatitis C, Malaria, Respiratory Syncytial Virus and
Ebola [12–15].
In addition to establishing an appropriate vector, suitable vac-
cine antigen candidates need to be identiﬁed. The spread of the HIV
pandemic is largely due the virus’s ability to evade immune surveil-
lance by constantly mutating. It has been shown previously that
naturally induced T cell responses to the HIV protein Gag, decreased
viral load [16] and that a breadth of responses to many HIV proteins
offered better protection, especially to HIV protein domains that are
highly conserved and impose a survival weakness if mutated [17].
Of those proteins, Gag, Pol and Nef have more highly conserved
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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omains and responses to these proteins have shown promise as
rotective vaccine candidates [16,18–22].
In this study we have engineered two HIV vaccine vector can-
idates chAd3 and chAd63 to carry a mosaic polyprotein antigen
ombining epitopes from HIV proteins Gag, Pol and Nef (GPN). We
ave studied the immune responses to the vaccines across the gag,
ol and nef elements and compared the chAd3 and chAd63 vectored
accines as potential HIV vaccine candidates.
. Materials and methods
.1. Recombinant ChAd production
ChAd vector systems were provided by Okairos (Italy) and have
een previously described [23,24]. GPN transgene [25] was sub-
loned by homologous recombination from Okairos pShuttle (pSh)
ntermediate according to manufacturer’s instructions.
Viruses were generated in Procell 92 cells and puriﬁed by
 rounds of CsCl gradient ultracentrifugation and dialysed into
kairos-recommended formulation buffers. Viruses were ﬁlter
terilised, stored at −80 ◦C; aliquots were used once only.
Viruses were titred for infectious units (IU)/mL by infection
f 293A cells followed by anti-Hexon immunoassay QuickTiterTM
denovirus Titer Immunoassay kit (Cell Biolabs). Viruses were
dditionally titred for virus particles (VP)/mL by treatment with
.1% ﬁnal SDS and OD260 measurement. VP/mL are calculated as
.1 × 10e12 VP/mL per OD260 unit [26].
.2. Gene-speciﬁc PCR
Viral genome plasmid or puriﬁed viruses were treated with
nal 0.1% SDS at 56 ◦C for 10 min  before transgene speciﬁc PCR.
or full-length GPN mosaic primers were ATGGCCGCCAGAGC-
TC and TCATCACTTGGCCCGGTG; env gene detection primers
ere GCCACCATGGACCGGGC and TCATCAGCTGTCCAGAGCC. For
ested PCR primers for GPN were GGAAATCTGCGGCAAGAAGG and
TTCTTCCTCTTCCTGGGCTTC and for env GCCACCATGGACCGGGC
nd CTGCTGCTGTTGCTCTTGGT. Virus subtype matched plasmid or
iral vectors encoding the env gene were used as negative con-
rols. In both plasmid and viral PCRs Shuttle plasmids (pShGPN
nd pShenv) known to contain the full-length GPN and env genes,
espectively were used in PCR as positive, molecular weight con-
rols.
.3. Protein expression from cells infected with viral vectors
A549 cells were infected with a multiplicity of infection (MOI) of
0 IU/cell of puriﬁed viruses or transiently transfected with pShGPN
sing Lipofectamine 2000 (Life Technologies). On d2 post-infection
ells were treated with Brefeldin A (Bref A) for 4 h followed by intra-
ellular staining using BD Cytoﬁx/Cytoperm kit (BD Biosciences)
nd anti-gag PE-conjugated antibody (KC57-RD1, Beckman Coul-
er).
Infected cell lysates, were analysed by Western blot using Rab-
it anti-HIV1 (MN) p24 anti-gag antibody (NIBSC) and secondary
oat anti-rabbit IRDye®680RD antibody (LI-COR). Membranes were
nalysed using the LI-COR Odyssey® scanner.
.4. MiceC57BL/6 mice were purchased from Harlan (UK); 6–8 week old
emales were used. All in vivo procedures were performed in accor-
ance with Royal Holloway and Home Ofﬁce regulations for animal
xperimentation. (2015) 7283–7289
2.5. Spleen cell isolation
Splenocyte suspensions were obtained using a glass
homogeniser (Fisher) with RPMI containing 10% FBS, 100 IU/ml
penicillin and 0.1 mg/ml streptomycin (Gibco). Cells were treated
with red cell lysis buffer as directed (Sigma-Aldrich). Live cells
were counted using Trypan blue exclusion.
2.6. Peptides
Individual HIV-ZM96 gag overlapping peptides (15-mers over-
lapping by 10 amino acids) were provided by NIBSC, UK and
dissolved in water. Reconstituted individual overlapping peptides
for HIV-ZM96 Pol 5′, Nef and Pol 3′ were provided by the Interna-
tional Aids Vaccine Initiative (IAVI). The peptides were pooled into
peptide pool matrices such that each peptide was  present in 2 pools
and were used at a concentration of 1 g/mL. Individual peptides
were used at the same concentration.
2.7. IFN ELISpot
HIV speciﬁc IFN- T cell responses were determined by restim-
ulation of splenocytes with peptides and quantiﬁed by anti-mouse
IFN- ELISpot (Mabtech AB, Sweden). Spots were visualised using
ABS peroxidase-avidin-biotin complexes (Vector Labs, UK) and
developed by addition of AEC (Sigma Aldrich) substrate solu-
tion. Plates were dried overnight and read using an AID ELISpot
reader (AutoImmun Diagnostika, Germany). Lipopolysaccharide
(LPS, 1 mg/mL) and water stimulated cells served as positive and
negative controls, respectively.
3. Results
3.1. Characterisation of ChAd-GPN plasmid and viral genomes
and GPN protein expression
To conﬁrm successful recombination of the GPN gene into the
chAd3 and 63 viral vectors, vector plasmids were subjected to gene-
speciﬁc PCR using primers binding and amplifying the full-length
GPN gene (Fig. 1A). Both chAd3 and 63-GPN plasmid genomes
(Fig. 1A, top panel) and puriﬁed viruses (Fig. 1A, bottom panel) were
shown to produce bands consistent with the expected 4245 bp
molecular weight of the full-length GPN mosaic gene. No PCR ampli-
ﬁcation was  seen with subtype matched, negative control chAd3
and 63-env viral plasmids, or viruses though bands consistent with
the predicted molecular weight of the env gene (1968 bp) were
produced by env speciﬁc PCR. Vector genomes were veriﬁed for
integrity using restriction mapping and transgenes were sequenced
(data not shown).
To ensure infectivity and GPN protein expression, A549 cells
were infected with 50 IU/cell of chAd3-GPN or chAd63-GPN or as
negative controls with chAd3-env or chad63-env puriﬁed viruses.
Cells infected with chAd3-GPN and chAd63-GPN produced 48.2%
and 79.3% Gag positive cells, respectively (Fig. 1B, right hand plots)
whereas cells infected with negative control, subtype-matched env
bearing viruses were negative for anti-gag antibody staining (mid-
dle plots).
Fig. 1C shows protein bands at 200 kDa consistent in size with
that detected in pShGPN transfected cells conﬁrming that infection
with these viruses drives the expression of gag-containing GPN
polyprotein. GPN protein bands were not detected in negative-
control subtype-matched chAd3-env and 63-env infected cells
though Env protein expression was  detected (data not shown). The
combined FACS and western analyses show that the chAd3-GPN
S. Herath et al. / Vaccine 33 (2015) 7283–7289 7285
Fig. 1. Recombination of GPN transgene to chimp adenoviral vector plasmids and viral genomes and protein expression. (A) Top panel: PCR analysis for full-length GPN gene (top
gel)  or negative control env gene (bottom gel) on chAd plasmids (p.chAd) 3-GPN and 63-GPN and subtype-matched negative control plasmids 3-env and 63-env. Bottom panel:
Nested  PCR analysis for full-length GPN gene (top gel) or negative control env gene (bottom gel) on puriﬁed chimp adenovirus (v.chAd) 3- and 63-GPN and subtype matched
negative control puriﬁed chimp adenovirus 3-env and 63-env. Positive, molecular weight control in each PCR was plasmid pShuttle-env or pShuttle-GPN. (B) A549 cells were
left  uninfected or infected with an MOI  of 50 (IU/cell) of chAd3-GPN and chAd63-GPN or negative control chAd3-env and 63-env puriﬁed viruses. On d2 post-infection cells
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ell  lysates were analysed for gag expression by Western blot using an anti-gag p24
nd 63-GPN viruses can infect cells in vitro and result in expression
f the GPN polyprotein.
.2. Response, dose and route of injection
To determine whether there were immune responses to the
IV transgene, splenocytes were stimulated with mega pools,
ontaining all the peptides, for Gag, Pol 5′, Nef and Pol 3′. Both
ectors elicited responses to all mega pools except Nef, where
nly responses from chAd3 vaccinated animals were observed.
esponses to both Pol mega pools were also higher in chAd3
njected animals (Fig. 2A). As many authors comparing vectors for
accination inject a VP dose to determine immune responses, while
e used infectious units (IU), we determined if the VP dose was
imilar for both vectors in our model. We  analysed the VP:IU ratio
n our vectors and found a tenfold difference between the two vec-
ors (chAd3 VP:IU is 156 and chAd63 VP:IU is 14). To compensate for
his, we repeated the experiment using mice vaccinated with either
 × 108 IU of chAd3-GPN or 1 × 109 IU chAd63-GPN. Responses to
he mega pools were more comparable at the higher dose of chAd63
hough there was still no response to the Nef mega pool in chAd63
accinated animals (Fig. 2B). Subsequently all experiments were
arried out using 1 × 108 IU of chAd3-GPN and 1 × 109 IU chAd63-
PN.
Previous work has shown that the route of injection cannﬂuence the immune response, due to the presence or absence
f different antigen presenting cells at the site of injec-
ion. To determine whether the route of injection played a
ole in immune responses with chAd vectors, we  injectedor each infection are shown. (C) A549 cells were infected and on d2 post-infection
ody.
chAd3 either subcutaneously or intra-muscularly and compared
responses to gag peptide pools. Comparable responses were seen
between the vaccinations suggesting that the route of injec-
tion did not signiﬁcantly inﬂuence the outcome of the immune
response (Fig. 2C). Consequently all vaccinations were carried out
subcutaneously.
3.3. Immunogenicity of the chAd vectors
To ascertain whether there were any speciﬁc differences in the
immune response between the two vectors, mice were vaccinated
with either chAd3 or chAd63 and responses to smaller peptide
pools against Gag, Pol 5′, Nef and Pol 3′ were assessed. There were
no differences in responses to Gag, Pol 5′ and Pol 3′ peptide pools in
chAd3 and chAd63 vaccinated mice (Fig. 3A, C and G, respectively),
but only chAd3 vaccinated animals responded to Nef peptide pools
(Fig. 3E). To determine whether there were any differences at the
epitope level, responses to individual peptides were analysed. No
signiﬁcant differences were observed in response to Gag, Pol 5′
and Pol 3′ individual peptides (Fig. 3B, D and H, respectively) and
only chAd3 vaccinated mice responded to Nef individual peptides
(Fig. 3F).
Epitope mapping of Gag, Pol and Nef was cross-checked against
the individual peptide responses observed and possible epitopes
were identiﬁed (Table 1). Table 1 shows that most of the possible
epitopes were Kb restricted and 8 amino acids long. Identiﬁcation
of the actual epitope requires peptide synthesis along the epitope
region and was beyond the scope of this work.
7286 S. Herath et al. / Vaccine 33 (2015) 7283–7289
Fig. 2. chAd3-GPN and 63-GPN induce IFN responses against mega pools that are dose dependent but route independent. Mice were vaccinated with (A) 1 × 108 IU of either
chAd3-GPN  (black bar) or chAd63-GPN (grey bar) or with (B) 1 × 108 IU chAd3-GPN (black bar) or 1 × 109 IU chAd63-GPN (grey hatched bar). Splenocytes were harvested
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plenocytes were harvested and stimulated with Gag peptide pools. IFN productio
xperiments, and graph C represents 6 mice ± SD from 2 separate experiments.
. Discussion
Our studies aimed to determine the immunogenicity of two
hAd vector vaccines encoding a transgenic antigen with poten-
ial epitopes from Gag, Pol and Nef proteins (GPN). When injected
t an equal infectious unit dose, both vectors induced a response
o each of the transgene products, except for Nef, and chAd3 stim-
lated a higher IFN response compared to chAd63 (Fig. 2). The
agnitude of the responses in chAd63 vaccinated animals was  aug-
ented by increasing the dose of chAd63 though there was  still
o response to the Nef transgene product, implying that chAd63
ight be less immunogenic. ChAd63 was similarly shown to be
ess immunogenic than ChAd3 in producing responses to SIV-gag
9].
On further analysis, it was discovered that increasing the dose
f chAd63 tenfold resulted in both preparations of chAd3 and
hAd63 vaccines containing a similar number of viral particles (VP)
chAd3: 1.59 × 1010 VP/mL and chAd63: 1.4 × 1010 VP/mL). During
he preparation of the vectors it was noted that the chAd3 prepa-
ation resulted in an infectious unit to viral particle (IU:VP) ratio
f 1:159 while the chAd63 preparation resulted in an IU:VP ratio
f 1:14. Hence increasing the dose of chAd63 tenfold resulted in
imilar viral particle numbers and it is unclear whether defective
irus particles provided an adjuvant effect. Defective adenovirus, in
articular Hexon protein, has been previously shown to be a potent
djuvant [27].
The presence of IFN secreting cells to key peptide pools and
ndividual peptides to each transgene product were analysed and
e found that both vectors responded to the same peptides except
or Nef peptides, where, interestingly, only cells from chAd3 vac-
inated animals responded. There is currently no literature on thef chAd3-GPN either subcutaneously (black bar) or intra-muscularly (Grey bar) and
 determined by ELISpot and graphs A and B represent 9 mice ± SD from 3 separate
expression of the nef transgene in chAd vectors and we are the ﬁrst,
to the best of our knowledge, to identify a difference in immune
responses to the Nef transgene product between two  chAd vectors.
Both vectors’ transgenes have been fully sequenced and have been
shown to produce proteins consistent in size with the full-length
GPN transgene (Fig. 1C). However, we have not statistically quan-
tiﬁed the level and duration of expression of GPN from each vector
and expression of antigen transcripts was seen to vary between
chAd3 and 63 vectors expressing SIV-gag [10].
Computational analysis of the epitopes expressed by the
C57BL/6 mouse strain for Gag, Pol 5′, Nef and Pol 3′ indicated that
some peptides contained more than 1 epitope (Table 1). Analysis of
our ﬁndings suggest that vaccination with chAd vectors results in
the presentation of a dominant peptide in the Gag and Nef trans-
gene product (peptide 8 for Gag and peptide 59 for Nef) due to the
higher responses observed compared to the other peptides within
the transgene. The limitations of our experimental design do not
make it possible to determine which epitopes are being expressed
as this would require designing pentamers against each potential
epitope.
Taken together our results showed that both chAd3 and chAd63
induced responses against a maximum of 6 epitopes within HIV
Gag and 5 epitopes within Pol with 3 further epitopes within
Nef for chAd3. It is well recognised that HIV circulate with large
genetic variability within strains and the requirement of a suit-
able prophylactic vaccine would be to induce a broad response
to many epitopes implying that chAd3 would be a better vac-
cine vector. However, it must be noted that our experiments did
not investigate the polyfunctionality of the responding cells nor
did we determine the magnitude of innate immune responses.
Quinn et al. [9] show that both chAd3 and chAd63 induce a low
S. Herath et al. / Vaccine 33 (2015) 7283–7289 7287
Fig. 3. Comparable IFN responses and identiﬁcation of individual peptides. Mice were vaccinated with either 1 × 108 IU of chAd3-GPN (black bar) or 1 × 109 IU of chad63-GPN
(grey  bar). Splenocytes were harvested and stimulated with the indicated peptide pools (A, C, E and G) or the individual peptides (B, D, F and H). IFN production was
determined by ELISpot and graphs A and B represent 9 mice ± SD from 3 separate experiments and graph (C–H) represents 8 mice ± SD from 2 separate experiments.
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Table 1
Identiﬁcation of possible epitopes. Computational analysis (http://www.mpiib-berlin.mpg.de/MAPPP/) of possible epitopes by C57BL/6 mice against the HIV transgene were
cross-checked against the peptide sequence of individual peptides that were positive for IFN- production.
Transgene Peptide no. Peptide sequence Possible epitope Restriction
Gag 8 GTEELRSLYNTVATLYCVHE GTEELRSL/LRSLYNTVA H2Kb/H2Kb
17 EKAFSPEVIPMFTALSEGAT FSPEVIPMF/VIPMFTAL H2Kb/H2Kb
30 EPFRDYVDRFFKTLRAEQAT VDRFFKTLR H2Kb
31 FKTLRAEQATQEVKNWMTDT QEVKNWMTD H2Kb
Pol 5′ 32 GTVLVGPTPVNIIGR VGPTPVNII H2Db
69 ESFRKYTAFTIPSTN RKYTAFTI H2Kb
Nef 29 GKWSKSSIVGWPAVR KWSKSSIV/SIVGWPAV H2Kb/H2Kb
30 KSSIVGWPAVRERIR SIVGWPAV H2Kb
R 
KL 
f
o
m
v
s
n
s
u
p
a
d
w
v
b
(
i
c
a
v
a
s
T
c
i
i
P
B
a
r
t
r
s
p
s
v
A
t
t
J
b
o
R
[
[
[
[
[
[
[
[
[
[
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59 ETFYVDGAANRET
requency of IFN-only producing T cells but a high percentage
f polyfunctional T cells to a dominant HIV gag peptide. Further-
ore, variation of type I IFN responses between different rAd
ectors was reported and correlated to immunogenicity [10]. Con-
equently both chAd3 and chAd63 could elicit immune responses
ot measured in this study. The fact that both vectors recognise
imilar epitopes diminishes the possibility of both vectors being
sed in a single vaccine to broaden the response to the transgene
roduct.
In addition to designing a vaccine, the route of injection is also
n important factor in assessing efﬁcacy [28–32]. To this end we
etermined whether the chAd vectors induced differing responses
hen injected subcutaneously or intramuscularly. In line with pre-
ious work, there was no signiﬁcant difference in the magnitude or
readth of IFN responses observed with either route of injection
Fig. 2) [30,33]. Professional antigen presenting cells are abundant
n the subcutaneous layer of the skin but are less numerous in mus-
le tissue [34]. However the observation that both vectors induce
 similar response despite the route of injection suggest that both
ectors are recognised in muscle tissue. Intramuscular injections
re preferred as a vaccination route due to the adequate blood
upply to the muscle, which aids in the dispersion of the product.
he result that both vectors induced an immune response in mus-
le tissue bodes well for chAd vectors being used in intramuscular
njections.
Like other adenoviruses, both chimpanzee adenovirus vectors
nduced an immune response to the transgene products Gag and
ol, with hierarchal epitope dominance seen in the Gag product.
oth vectors responded to similar epitopes for Gag and Pol elements
nd the route of injection did not alter the outcome of immune
esponses. Interestingly, only chAd3 vaccination induced responses
o the Nef transgene product suggesting that chAd3 may  be supe-
ior as a vaccine vector candidate. Taken together, our results
uggest that chimpanzee adenoviruses with their low global sero-
revalance demonstrable immunogenicity in various species and
afety in human trials to date could be good vaccine candidates as
iral vectors for HIV vaccines.
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